Here are the 10-K annual reports from Foghorn Therapeutics Inc. (FHTX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow FHTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FHTX filings page.
Foghorn Therapeutics is a clinical-stage biotechnology company developing precision medicines that correct abnormal gene expression by targeting the chromatin regulatory system, which is implicated in roughly half of all cancers. Its proprietary Gene Traffic Control® platform combines genomics, epigenomics, AI tools and protein degradation technologies to identify genetically driven dependencies and drug them selectively.
The lead program, FHD-909, is a first-in-class oral SMARCA2-selective inhibitor being developed with Eli Lilly for SMARCA4-mutated cancers, particularly non-small cell lung cancer, with a Phase 1 trial underway after first dosing in October 2024. Foghorn and Lilly are also advancing a SMARCA2 degrader and additional oncology discovery programs.
The pipeline includes selective degraders of CBP, EP300 and ARID1B aimed at tumor types where paralog mutations create synthetic lethal vulnerabilities across solid tumors and hematologic cancers. Management believes the current portfolio could benefit more than 500,000 cancer patients and supports the potential to file four INDs over the next two years. As of December 31, 2025, the company had 106 employees and remains pre-commercial with no approved products, highlighting typical biotechnology risks such as ongoing losses, funding needs, clinical uncertainty and strong competition.